Results of the treatment of anterior pelvic organ prolapse using the Perigee® system.
To study the efficacy and safety of the Perigee® System for the treatment of anterior vaginal prolapse in our experience with a medium term follow-up. Prospective analysis on 48 consecutive patients with stage II-IV cystocele diagnosed from June 2006 until June 2009 using the Pelvic Organ Prolapse Quantitation classification without other associated prolapses. All diagnoses were done by a single urological specialist and follow-up is between 3 to 6 years. The questionnaire Patient Global Impression of Improvement was carried out before surgery, at the first follow up checking at one month, and at 6 and 12 months. The variables evaluated were age, presence of obesity, parity, prior hysterectomy, ASA class and stage of prolapse. The result, evaluating the questionnaire Patient Global Impression of Improvement, was cured or improved in 40 (83.3%) patients and 87.5% according to the Pelvic Organ Prolapse Quantitation, with a recurrence rate of 6.25%. Intraoperative complications were observed in 12.5% of the patients, postoperative in 4.2% and 41.5% after hospital discharge, pain being the most common complication (16.6%). The key variables for procedural failure were age 65 years >, obesity, parity ≥ 2, prolapse stage ≥ III and prior hysterectomy (p <0.05). In our series the Perigee® System allows anatomic repair with less morbidity, hospital stay and recovery time.